Cancer immunoediting and resistance to T cell-based immunotherapy

By Jake S. O’Donnell, M. Teng, M. Smyth. Nature Reviews Clinical Oncology, 2018

1,476 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy (2022, background): “One of the main factors contributing to primary resistance to ICIs is the lack of tumor-infiltrating T cells, which is one of the characteristics of “cold” tumors whose TME is infiltrated with various immunosuppressive cells such as stromal cells, M2 macrophages, MDSCs, and Treg cells.(407,408) ICIs”
Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer (2021, background): “Immunotherapies, harnessing the dual roles of the immune system in battling cancer, have emerged as new pillars within oncotherapy.(324,325) To date, CAFs have been found mainly to regulate and rewire the TME to favor the malignant biological properties of tumors through the interaction of CAFs and ”